Stevanato Group S.p.A. (STVN)

NYSE: STVN · IEX Real-Time Price · USD
18.22
+0.12 (0.66%)
Aug 12, 2022 4:00 PM EDT - Market closed
0.66%
Market Cap 4.82B
Revenue (ttm) 940.45M
Net Income (ttm) 127.98M
Shares Out 264.70M
EPS (ttm) 0.51
PE Ratio 36.08
Forward PE 37.88
Dividend $0.05 (0.29%)
Ex-Dividend Date Jun 13, 2022
Volume 189,782
Open 18.32
Previous Close 18.10
Day's Range 17.75 - 18.45
52-Week Range 13.36 - 29.18
Beta n/a
Analysts Buy
Price Target 20.26 (+11.2%)
Earnings Date Aug 4, 2022

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L. [Read more...]

Industry Medical Instruments & Supplies
IPO Date Jul 16, 2021
Employees 4,652
Stock Exchange NYSE
Ticker Symbol STVN
Full Company Profile

Financial Performance

In 2021, STVN's revenue was 843.92 million, an increase of 27.47% compared to the previous year's 662.04 million. Earnings were 134.32 million, an increase of 71.08%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is 20.26, which is an increase of 11.20% from the latest price.

Price Target
$20.26
(11.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group Reports Second Quarter 2022 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group to Report Second Quarter 2022 Financial Results on August 4, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

JAZZ vs. STVN: Which Stock Is the Better Value Option?

JAZZ vs. STVN: Which Stock Is the Better Value Option?

Other symbols: JAZZ

JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?

JAZZ vs. STVN: Which Stock Is the Better Value Option?

Other symbols: JAZZ

Stevanato Group Releases Sustainability Report 2021, Highlighting the Environmental, Social and Governance (ESG) Perf...

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) announces the publication of its Sustainability Report 2021.

Stevanato Group Announces Voting Results from its Annual General Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and...

Stevanato Group to Present at Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group Adding New Capacity in Italy Amid Growing Demand for Its Market-Leading Solutions

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, an...

Stevanato Group Reports First Quarter 2022 Financial Results

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group Publishes Materials for 2022 Annual General Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, a...

Stevanato Group and Owen Mumford Sign Exclusive Collaboration Agreement for the Innovative Aidaptus® Auto-Injector

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sc...

Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions ...

PIOMBINO DESE, Italy & SANTA BARBARA, Calif.--(BUSINESS WIRE)--Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, ...

Stevanato Group to Report First Quarter 2022 Financial Results on May 10, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group Files Amendment No.1 to Its 2021 Annual Report on Form 20‑F/A

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, a...

Stevanato Group to Create Manufacturing Hub in China

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN) (the “Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology an...

Stevanato Group Reports Record 2021 Revenue of €843.9 million

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Q4 and FY 2021 STVN Earnings

Stevanato Group Announces Agreement With BARDA for the Expansion of Vial Production to Create Industrial Base Capabil...

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences ...

Stevanato Group to Report Fourth Quarter Financial Results on March 8, 2022

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Q4 & YE 2021 Earnings notification

Stevanato Group Appoints Riccardo Butta as President, Americas

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, t...

Stevanato Group Extends Pen Injector Technology Licensing Agreement With Haselmeier

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, h...

Stevanato Group Announces Expansion of Corporate Headquarters

PIOMBINO DESE (PD), Italy--(BUSINESS WIRE)--Stevanato Group (NYSE: STVN) (“the Company”), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnolo...

Vaccine vial maker Stevanato ticks up 2021 guidance after Q3 results

Italian vaccine vial maker Stevanato on Tuesday slightly improved its guidance on full-year results after reporting a 37% increase in third quarter revenue.

Stevanato Group Reports Strong Third Quarter 2021 Revenue and Financial Results and Updates Full Year 2021 Guidance

PIOMBINO DESE, Italy--(BUSINESS WIRE)--STVN Q3 21